Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

China Medical University Hospital (Taiwan) and Shine-On Biomedical Co. developed SOB100, the world's first HLA-G targeted ...

MEDSIR announces positive results from TUXEDO-3 trial of patritumab deruxtecan in patients with active brain metastases and leptomeningeal disease: Chicago Monday, June 9, 2025, 1 ...